Screening for latent tuberculosis before tumour necrosis factor antagonist therapy
نویسندگان
چکیده
منابع مشابه
Screening for latent tuberculosis before tumour necrosis factor antagonist therapy.
References 1 Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J 2014; 44: 1132–1148. 2 Pullerits T, Ternesten-Hasséus E, Johansson EL, et al. Capsaicin cough threshold test in diagnostics. Respir Med 2014; 108: 1371–1376. 3 Faruqi S, Thompson R, Wright C, et al. Quantifying chronic cough: objective versus subjec...
متن کاملImportance of tuberculosis screening before inhibiting tumour necrosis factor-alpha therapy.
INTRODUCTION There has been an increase in the incidence of tuberculosis infection in recent years, due to the increasing use of drugs inhibiting tumour necrosis factor-alpha (anti-TNFα) in the treatment of inflammatory diseases. CASE REPORT We report the case of a male patient being treated with infliximab (anti-TNFα) who developed disseminated tuberculosis with ocular involvement. CONCLUS...
متن کاملPulmonary granulomas after tumour necrosis factor alpha antagonist therapy.
Tumour necrosis factor alpha (TNFalpha) antagonists are an established therapeutic option in Crohn's disease and rheumatoid arthritis. In recently published studies these agents have been used with great success, but little is known about any side effects or long term consequences. They increase the frequency of infections with mycobacteria, where TNFalpha is thought to be an important host def...
متن کاملThe risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist thera...
متن کاملSinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
INTRODUCTION In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2015
ISSN: 0903-1936,1399-3003
DOI: 10.1183/09031936.00020315